Logo image of PRCT

PROCEPT BIOROBOTICS CORP (PRCT) Stock Fundamental Analysis

NASDAQ:PRCT - Nasdaq - US74276L1052 - Common Stock - Currency: USD

55.62  +2.77 (+5.24%)

After market: 54.47 -1.15 (-2.07%)

Fundamental Rating

4

Overall PRCT gets a fundamental rating of 4 out of 10. We evaluated PRCT against 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of PRCT is average, but there are quite some concerns on its profitability. PRCT is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year PRCT has reported negative net income.
In the past year PRCT has reported a negative cash flow from operations.
In the past 5 years PRCT always reported negative net income.
In the past 5 years PRCT always reported negative operating cash flow.
PRCT Yearly Net Income VS EBIT VS OCF VS FCFPRCT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

PRCT has a Return On Assets (-17.12%) which is in line with its industry peers.
With a Return On Equity value of -22.73%, PRCT perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
Industry RankSector Rank
ROA -17.12%
ROE -22.73%
ROIC N/A
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
PRCT Yearly ROA, ROE, ROICPRCT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

With a decent Gross Margin value of 61.07%, PRCT is doing good in the industry, outperforming 62.11% of the companies in the same industry.
PRCT's Gross Margin has improved in the last couple of years.
PRCT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.07%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
PRCT Yearly Profit, Operating, Gross MarginsPRCT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

6

2. Health

2.1 Basic Checks

PRCT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRCT has more shares outstanding
The number of shares outstanding for PRCT has been increased compared to 5 years ago.
PRCT has a better debt/assets ratio than last year.
PRCT Yearly Shares OutstandingPRCT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PRCT Yearly Total Debt VS Total AssetsPRCT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

An Altman-Z score of 13.36 indicates that PRCT is not in any danger for bankruptcy at the moment.
PRCT's Altman-Z score of 13.36 is amongst the best of the industry. PRCT outperforms 93.16% of its industry peers.
PRCT has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PRCT (0.13) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z 13.36
ROIC/WACCN/A
WACC8.92%
PRCT Yearly LT Debt VS Equity VS FCFPRCT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 9.07 indicates that PRCT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.07, PRCT belongs to the top of the industry, outperforming 91.05% of the companies in the same industry.
PRCT has a Quick Ratio of 8.01. This indicates that PRCT is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PRCT (8.01) is better than 91.05% of its industry peers.
Industry RankSector Rank
Current Ratio 9.07
Quick Ratio 8.01
PRCT Yearly Current Assets VS Current LiabilitesPRCT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

7

3. Growth

3.1 Past

PRCT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.81%, which is quite good.
PRCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.36%.
PRCT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.20% yearly.
EPS 1Y (TTM)19.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
Revenue 1Y (TTM)59.36%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%55.28%

3.2 Future

PRCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.69% yearly.
The Revenue is expected to grow by 25.11% on average over the next years. This is a very strong growth
EPS Next Y12.44%
EPS Next 2Y20.26%
EPS Next 3Y20.44%
EPS Next 5Y17.69%
Revenue Next Year44.33%
Revenue Next 2Y38.38%
Revenue Next 3Y34.52%
Revenue Next 5Y25.11%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
PRCT Yearly Revenue VS EstimatesPRCT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
PRCT Yearly EPS VS EstimatesPRCT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PRCT. In the last year negative earnings were reported.
Also next year PRCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRCT Price Earnings VS Forward Price EarningsPRCT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRCT Per share dataPRCT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PRCT's earnings are expected to grow with 20.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.26%
EPS Next 3Y20.44%

More info and screens

0

5. Dividend

5.1 Amount

PRCT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROCEPT BIOROBOTICS CORP

NASDAQ:PRCT (5/2/2025, 8:18:00 PM)

After market: 54.47 -1.15 (-2.07%)

55.62

+2.77 (+5.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)04-24 2025-04-24/bmo
Earnings (Next)07-30 2025-07-30/amc
Inst Owners94.03%
Inst Owner Change-2.74%
Ins Owners4.59%
Ins Owner Change-1.59%
Market Cap3.08B
Analysts82.35
Price Target94.29 (69.53%)
Short Float %11.68%
Short Ratio5.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.52%
Min EPS beat(2)-4.69%
Max EPS beat(2)19.73%
EPS beat(4)3
Avg EPS beat(4)7.81%
Min EPS beat(4)-4.69%
Max EPS beat(4)19.73%
EPS beat(8)5
Avg EPS beat(8)1.39%
EPS beat(12)7
Avg EPS beat(12)3.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.89%
Min Revenue beat(2)0.18%
Max Revenue beat(2)7.6%
Revenue beat(4)4
Avg Revenue beat(4)4.27%
Min Revenue beat(4)0.18%
Max Revenue beat(4)7.6%
Revenue beat(8)7
Avg Revenue beat(8)2.93%
Revenue beat(12)11
Avg Revenue beat(12)5.74%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.35%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-38.3%
EPS NY rev (1m)0%
EPS NY rev (3m)-14.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.71
P/FCF N/A
P/OCF N/A
P/B 7.65
P/tB 7.67
EV/EBITDA N/A
EPS(TTM)-1.7
EYN/A
EPS(NY)-0.97
Fwd EYN/A
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)-1.79
OCFYN/A
SpS4.06
BVpS7.27
TBVpS7.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.12%
ROE -22.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.07%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-26.26%
ROE(3y)-34.89%
ROE(5y)-42.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y9.87%
GM growth 5YN/A
F-Score5
Asset Turnover0.42
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 84.24%
Cap/Sales 1.96%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.07
Quick Ratio 8.01
Altman-Z 13.36
F-Score5
WACC8.92%
ROIC/WACCN/A
Cap/Depr(3y)279.88%
Cap/Depr(5y)173.09%
Cap/Sales(3y)8%
Cap/Sales(5y)5.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.76%
EPS Next Y12.44%
EPS Next 2Y20.26%
EPS Next 3Y20.44%
EPS Next 5Y17.69%
Revenue 1Y (TTM)59.36%
Revenue growth 3Y86.75%
Revenue growth 5Y105.2%
Sales Q2Q%55.28%
Revenue Next Year44.33%
Revenue Next 2Y38.38%
Revenue Next 3Y34.52%
Revenue Next 5Y25.11%
EBIT growth 1Y11.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.22%
EBIT Next 3Y32.75%
EBIT Next 5YN/A
FCF growth 1Y22.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.14%
OCF growth 3YN/A
OCF growth 5YN/A